Hangzhou Edcheng Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the safety and tolerability of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors, observe the occurrence of DLT, and determine the MTD and RP2D. Secondary objective: To preliminarily obtain the pharmacokinetic parameters of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors (only the first part). Preliminary evaluation of the effectiveness of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors

Primary purpose: To observe the tolerance and safety of AL8326 after multiple administration in patients with advanced small cell lung cancer (including a small amount of bladder cancer, breast cancer, gastrointestinal stromal tumor, bile duct cancer or other solid tumors), the DLT and MTD of the drug in humans, the reversibility of toxicity, and the relationship between toxicity and dose. Secondary purpose: To recommend appropriate dosage and regimen for Phase II clinical trials; to preliminarily analyze the efficacy in patients with advanced small cell lung cancer (including a small amount of bladder cancer, breast cancer, gastrointestinal stromal tumor, bile duct cancer or other solid tumors).

Main purpose: 1. To study the tolerance and safety of AL58805 after single and multiple administrations in patients with hematological tumors, to observe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in humans after administration, the reversibility of toxicity, and the relationship between toxicity and dose. 2. To preliminarily study and analyze the pharmacokinetic characteristics of AL58805 tablets in patients with hematological tumors; Secondary purpose: 1. To recommend appropriate dosage and regimen for Phase II clinical trials based on Phase I tolerance test and pharmacokinetic results; 2. To preliminarily evaluate the efficacy of AL58805 in patients with hematological tumors